Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Table 3 Relationship between serum concentration of biomarkers at baseline and disease progression at week 52

Biomarker	Concentration at baseline	Treatment	Disease progression at week 52		p-value
Biomarker	Concentration at baseline	Treatment	Yes	No	p-value
SP-D	Low	Pirfenidone	15 (19.2%)	63 (80.8%)	0.0949
	Low	Placebo	17 (33.3%)	34 (66.7%)	0.0949
	High	Pirfenidone	26 (32.5%)	54 (67.5%)	0.3605
	High	Placebo	21 (40.4%)	31 (59.6%)	0.3605
SP-A	Low	Pirfenidone	23 (28.0%)	59 (72.0%)	0.4394
	Low	Placebo	17 (34.7%)	32 (65.3%)	0.4394
	High	Pirfenidone	18 (23.7%)	58 (76.3%)	0.0807
	High	Placebo	21 (38.9%)	33 (61.1%)	0.0807
KL-6	Low	Pirfenidone	19 (26.0%)	54 (74.0%)	0.2430
	Low	Placebo	20 (37.0%)	34 (63.0%)	0.2430
	High	Pirfenidone	22 (25.9%)	63 (74.1%)	0.2397
	High	Placebo	18 (36.7%)	31 (63.3%)	0.2397

All patients were dichotomized by the median concentration of each biomarker at baseline to the high and low biomarker subgroups. The disease progression was defined by a > 10% relative decline in vital capacity from baseline and/or death. Fisher's exact test
SP surfactant protein, KL Krebs von den Lungen

ISSN: 1465-993X